CDC to Withdraw Emergency Use Authorization for RT PCR Test Because It Cannot Distinguish Between SARS-CoV-2 and the Flu

The CDC quietly announced last week that it was withdrawing its request to the FDA for Emergency Use Authorization (EUA) of the 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2.

Most of the public is probably unaware that similar to the current COVID-19 injections that are not yet approved by the FDA, but only given Emergency Use Authorization, so too the hundreds of diagnostic tests that supposedly detect COVID-19 are also NOT approved by the FDA, but only authorized via an EUA.

What is the reason the CDC is withdrawing its EUA request for the Real-Time RT-PCR Diagnostic Panel?

“CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.”

So there you have it. The CDC just basically admitted that many of the COVID-19 cases this past year could not be distinguished from “flu cases.”